We are live on ! Find out more
NERV icon

Minerva Neurosciences

23 hedge funds and large institutions have $7.51M invested in Minerva Neurosciences in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more call options, than puts

Call options by funds: $311K | Put options by funds: $189K

36.74% more ownership

Funds ownership: 5.76%42.5% (+37%)

30% less funds holding

Funds holding: 3323 (-10)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

54% less capital invested

Capital invested by funds: $16.3M → $7.51M (-$8.83M)

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

Holders
23
Holders Change
-10
Holders Change %
-30.3%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
6
Reduced
10
Closed
13
Calls
$311K
Puts
$189K
Net Calls
+$122K
Net Calls Change
-$36K
Name Holding Trade Value Shares
Change
Change in
Stake
B
26
Bailard
California
-$20K -3,050 Closed
SMH
27
Sanders Morris Harris
Texas
-$20K -3,000 Closed
Bank of New York Mellon
28
Bank of New York Mellon
New York
-$16K -2,463 Closed
TSS
29
Two Sigma Securities
New York
-$14K -2,140 Closed
Citadel Advisors
30
Citadel Advisors
Florida
-$12K -1,842 Closed
Cambridge Investment Research Advisors
31
Cambridge Investment Research Advisors
Iowa
-$12K -1,738 Closed
GLA
32
Good Life Advisors
Pennsylvania
-$8K -1,250 Closed
JP Morgan Chase
33
JP Morgan Chase
New York
-$319 -78 -96%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
-$442 -67 Closed
Simplex Trading
35
Simplex Trading
Illinois
+$1K +245 +4,083%

NERV Hedge Fund Activity: Q2 2022 in Review

23 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q2 2022, worth a combined $7.51M — down 54% from $16.3M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NERV and 3 opened new positions — a net loss of 10 holders — while 10 trimmed existing stakes and 6 added.

The largest buyer was Barclays, opening a new position worth an estimated $34.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $850K sold.

  • 23 institutional investors held Minerva Neurosciences (NERV) as of Q2 2022, down from 33 in Q1 2022.
  • Funds reported $7.51M of Minerva Neurosciences stock for Q2 2022, down 54% quarter-over-quarter.
  • 3 funds opened new Minerva Neurosciences positions in Q2 2022 and 13 closed out, a net change of -10 holders.
  • The largest Minerva Neurosciences buyer in Q2 2022 was Barclays, an estimated $34.4K added.
  • The largest Minerva Neurosciences seller in Q2 2022 was Armistice Capital, an estimated $850K sold.

Based on aggregated 13F filings for Q2 2022.